Geron Corp. (GERN)

1.41
0.00 (0.00)
NASDAQ : Health Technology
Prev Close 1.41
Open 1.43
Day Low/High 1.40 / 1.45
52 Wk Low/High 0.95 / 6.99
Volume 1.26M
Avg Volume 1.66M
Exchange NASDAQ
Shares Outstanding 188.42M
Market Cap 261.91M
EPS -0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)
Geron Stung by Cancer Drug Blowup

Geron Stung by Cancer Drug Blowup

Geron's lead cancer drug appears to be done after two study setbacks.

5 Biotech Stocks Under $5 Blasting Off

5 Biotech Stocks Under $5 Blasting Off

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Geron Management Discusses Q2 2012 Results - Earnings Call Transcript

Geron Management Discusses Q2 2012 Results - Earnings Call Transcript

Geron Management Discusses Q2 2012 Results - Earnings Call Transcript

5 Biotech Stocks Poised for Breakouts

5 Biotech Stocks Poised for Breakouts

These stocks look ready to break out and trade higher from current levels.

22 Biopharma Stocks With Breakout Potential in 2012

22 Biopharma Stocks With Breakout Potential in 2012

TheStreet's Adam Feuerstein has compiled a list of drugs with crucial, stock-moving clinical trial catalysts for the remainder of 2012.

5 Stocks Under $10 Set to Spike Higher

5 Stocks Under $10 Set to Spike Higher

These under-$10 stocks look poised to trade higher from current levels.

Considering a Few Small-Cap Biotech Plays

The best way to invest in this sector is to accumulate small positions in at least a dozen firms.

More Biotech Lessons Learned From JPM 2012

More Biotech Lessons Learned From JPM 2012

Biotech stocks got off to a ripping start at the most closely watched healthcare conference of the year.

Geron Initiates Phase 2 Trial Of GRN1005 In Brain Metastases From Breast Cancer

Geron Initiates Phase 2 Trial Of GRN1005 In Brain Metastases From Breast Cancer

Geron Corporation (Nasdaq:GERN) today announced the initiation of GRABM-B ( GRN1005 Against Brain Metastases – Breast cancer), a Phase 2 clinical trial to evaluate GRN1005 in patients with brain metastases...

Geron Stock Hits New 52-Week Low (GERN)

Geron Stock Hits New 52-Week Low (GERN)

Geron Corporation (Nasdaq:GERN) hit a new 52-week low Thursday as it is currently trading at $1.58, below its previous 52-week low of $1.59 with 841,713 shares traded as of 11:10 a.m. ET. Average volume has been 1.6 million shares over the past 30 days.

Business Highlights

Business Highlights

Business Highlights

Geron's Stem Cell Bust Leaves Investors Holding the Bag

Geron's Stem Cell Bust Leaves Investors Holding the Bag

Wall Street not likely to fund new stem cell ventures in the wake of Geron's failure.

Geron Stock Gaps Down On Today's Open (GERN)

Geron Stock Gaps Down On Today's Open (GERN)

Shares of Geron Corporation (Nasdaq:GERN) were gapping down Tuesday morning with an open price 20.5% lower than Monday's closing price. The stock closed at $2.20 yesterday and opened today's trading at $1.75.

Geron Presents Final Phase 1 Clinical Data On GRN1005 At AACR-NCI-EORTC

Geron Presents Final Phase 1 Clinical Data On GRN1005 At AACR-NCI-EORTC

Geron Corporation (Nasdaq:GERN) today announced the final results of two Phase 1 clinical trials of GRN1005, the company’s lead LRP-directed peptide-drug conjugate (LRP-directed PDC), in patients with brain ...

Geron To Focus On Its Novel Cancer Programs

Geron To Focus On Its Novel Cancer Programs

Geron Corporation (Nasdaq: GERN) today announced that, effective immediately, the Company will focus on its first-in-class oncology programs.

Geron Corporation Reports 2011 Third Quarter Financial Results And Events

Geron Corporation Reports 2011 Third Quarter Financial Results And Events

Geron Corporation (Nasdaq: GERN) today reported financial results for the three and nine months ended September 30, 2011.

Geron Announces Conference Call To Discuss Third Quarter Financial Results And Highlights

Geron Announces Conference Call To Discuss Third Quarter Financial Results And Highlights

Geron Corporation (Nasdaq:GERN) will announce its financial results for the third quarter ended September 30, 2011 on Thursday, November 3, 2011, after the closing of the equity market.

Geron Announces Presentation At ECTRIMS/ACTRIMS

Geron Announces Presentation At ECTRIMS/ACTRIMS

Geron Corporation (Nasdaq: GERN) today announced data on the use of GRNOPC1, oligodendrocyte progenitors derived from human embryonic stem cells, for myelin repair in a non-human primate model.

Geron Presents Clinical Data Update From GRNOPC1 Spinal Cord Injury Trial

Geron Presents Clinical Data Update From GRNOPC1 Spinal Cord Injury Trial

Geron Corporation (Nasdaq: GERN) today announced two presentations on the company’s ongoing Phase 1 clinical trial of its human embryonic stem cell-based therapy, GRNOPC1, in patients with spinal cord injury.

5 Stocks With Big Insider Buying

5 Stocks With Big Insider Buying

Insiders at these companies have been loading up on shares of their own stocks lately.

Geron Stock Hits New 52-Week Low (GERN)

Geron Stock Hits New 52-Week Low (GERN)

Geron Corporation (Nasdaq:GERN) hit a new 52-week low Monday as it is currently trading at $2.02, below its previous 52-week low of $2.05 with 1.3 million shares traded as of 2:50 p.m. ET. Average volume has been 1.7 million shares over the past 30 days.

Geron Corporation Appoints John A. Scarlett As Chief Executive Officer And Director

Geron Corporation Appoints John A. Scarlett As Chief Executive Officer And Director

Geron Corporation (NASDAQ:GERN) announced today that its board of directors has appointed John A.

Geron Stock Hits New 52-Week Low (GERN)

Geron Stock Hits New 52-Week Low (GERN)

Geron Corporation (Nasdaq:GERN) hit a new 52-week low Wednesday as it is currently trading at $2.31, below its previous 52-week low of $2.36 with one million shares traded as of 3:56 p.m. ET. Average volume has been 1.6 million shares over the past 30 days.

Geron To Webcast Presentations At Upcoming Investor Conferences

Geron To Webcast Presentations At Upcoming Investor Conferences

Geron Corporation (Nasdaq: GERN) today announced that management will present a company overview at two upcoming investor conferences.

Expect a Tough October Market

The major indices will break through the August lows, but all bets are off if the Fed implements a full-blown QE3 program.

Geron Stock Hits New 52-Week Low (GERN)

Geron Stock Hits New 52-Week Low (GERN)

Geron Corporation (Nasdaq:GERN) hit a new 52-week low Friday as it is currently trading at $2.46, below its previous 52-week low of $2.47 with 789,359 shares traded as of 2:30 p.m. ET. Average volume has been 1.6 million shares over the past 30 days.

Geron Stock Hits New 52-Week Low (GERN)

Geron Stock Hits New 52-Week Low (GERN)

Geron Corporation (Nasdaq:GERN) hit a new 52-week low Monday as it is currently trading at $2.76, below its previous 52-week low of $2.85 with 362,545 shares traded as of 10:12 a.m. ET. Average volume has been 1.5 million shares over the past 30 days.

Geron Stock Hits New 52-Week Low (GERN)

Geron Stock Hits New 52-Week Low (GERN)

Geron Corporation (Nasdaq:GERN) hit a new 52-week low Friday as it is currently trading at $3.80, below its previous 52-week low of $3.85 with 112,289 shares traded as of 9:37 a.m. ET. Average volume has been 1.4 million shares over the past 30 days.

Geron Corporation Reports 2011 Second Quarter Financial Results And Events

Geron Corporation Reports 2011 Second Quarter Financial Results And Events

Geron Corporation (Nasdaq:GERN) today reported financial results for the three and six months ended June 30, 2011.

Geron Announces Conference Call To Discuss Second Quarter Financial Results And Highlights

Geron Announces Conference Call To Discuss Second Quarter Financial Results And Highlights

Geron Corporation (Nasdaq:GERN) will announce its financial results for the second quarter ended June 30, 2011 on Thursday, July 28, 2011, after the closing of the equity market.

TheStreet Quant Rating: D (Sell)